Related Experiment Video
Updated: Aug 8, 2026
10:04
Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
Published on: October 29, 2012
Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release
A S Schneider1, J E Nagel, S J Mah
1Department of Pharmacology and Neuroscience, Albany Medical College, NY 12208, USA.
European Journal of Pharmacology
|December 19, 1996
Summary
Ibogaine, an anti-addiction drug, selectively inhibits catecholamine release at nicotinic receptors. Higher doses also affect other release pathways, suggesting a specific mechanism at the receptor ion channel.
Area of Science:
- Neuropharmacology
- Cellular Neuroscience
Background:
- Ibogaine is investigated for its potential anti-addiction properties.
- Understanding ibogaine's cellular mechanisms is crucial for its therapeutic development.
Purpose of the Study:
- To investigate the effects of ibogaine on catecholamine release in cultured chromaffin cells.
- To elucidate the specific receptor interactions and mechanisms of action of ibogaine.
Main Methods:
- Utilized cultured chromaffin cells to study catecholamine release.
- Administered varying concentrations of ibogaine (1-10 microM and 100 microM).
- Measured stimulated catecholamine release to assess ibogaine's effects.
Main Results:
- Low ibogaine concentrations (1-10 microM) selectively inhibited nicotinic receptor-mediated catecholamine release.
- Higher ibogaine concentrations (100 microM) inhibited additional pathways of stimulated catecholamine release.
- Demonstrated a dose-dependent effect of ibogaine on catecholamine release.
Conclusions:
- Ibogaine exhibits a selective inhibitory action at the nicotinic acetylcholine receptor.
- The findings suggest ibogaine may act at the nicotinic acetylcholine receptor ion channel site.
- These results provide insight into ibogaine's potential anti-addiction mechanism.
Related Concept Videos
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:28Drugs Acting on Autonomic Ganglia: Blockers
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...